Role of SGLT2i in Heart Failure

Description

Outline -Heart Failure and Type 2 Diabetes Mellitus -T2DM treatments and heart failure -The pattern of heart failure in Kenya -Baseline characteristics differences in the trials -DAPA-HF features -Baseline characteristics of T2DM patients -DAPA-HF results -Drug development of SGLT2 inhibitors -A new approach to HFrEF treatments -Outcomes of SGTL2 HFrEF trials -Mechanisms of action in HFrEF -Clinical scenario

Objectives

Presenters

1. Dr. Harun Otieno
   International Cardiologist at AKUH Africa Heart Associates Nairobi, Kenya Pascar East Vice President KSTH Vice Chair
   Aga Khan University Hospital


2. Dr. Emma Karari
   Consultant Cardiologist
   University of Nairobi